跳至主要内容
临床试验/NCT00764803
NCT00764803终止不适用

Post-Market Study: The Efficacy of the 3DKnee™ System vs. the MJS Knee System

Encore Medical, L.P.1 个研究点 分布在 1 个国家目标入组 27 人开始时间: 2008年1月最近更新:
适应症

试验速览

阶段
不适用
状态
终止
入组人数
27
试验地点
1
主要终点
The survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System

研究概览

简要总结

The purpose of this study is to compare the survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System in a group of 600 patients for whom data collection is already under way.

详细描述

The purpose of this study is to compare the survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System in a group of 600 patients for whom data collection is already under way. Approximately 300 patients have already received the MJS™ knee system and data, as described below, has been collected for these patients over a period of two years. A second group of 300 patients will receive the Encore 3DKnee™ system over the next two years, and equivalent data will be collected for these individuals. A portion of the data has been collected over the past year, and now we would like to obtain permission from the patients to analyze these data as well as collect an additional year of data.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • This must be a primary knee replacement on this knee.
  • Patient is over 18 years of age or older
  • Patients must have one of the following
  • rheumatoid or traumatic arthritis OR
  • joint disease secondary to osteoarthritis
  • Patient is likely to be available for evaluation for the duration of the study
  • Able and willing to sign the informed consent and follow study procedures
  • Patient is not pregnant

排除标准

  • Is younger than 18 years of age
  • If there has been a total knee replacement on this knee in the past (no revisions allowed in study)
  • Overt infection
  • Alcoholism or other addictions
  • Muscular, neurological or vascular deficiencies which compromise the affected extremity
  • Marked bone loss
  • Materials sensitivity
  • Mental conditions that may interfere with the patient's ability to give an informed consent or willingness to fulfill the study requirements
  • Patient is pregnant

结局指标

主要结局

The survivorship and efficacy of the Encore 3DKnee™ system with that of the Encore MJS™ Knee System

时间窗: 2 year

次要结局

未报告次要终点

研究者

申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

进行中(未招募)
1 期
Estudio de fase III para evaluar la eficacia y la seguridad de docetaxel y prednisona con o sin lenalidomida en pacientes con cáncer de próstata resistente a la castración (CPRC).A PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF DOCETAXEL AND PREDNISONE WITH OR WITHOUT LENALIDOMIDE IN SUBJECTS WITH CASTRATE-RESISTANT PROSTATE CANCERPacientes con cáncer de próstata metastásico sin experiencia de quimioterapia y con elevación documentada del antígeno prostático específico (PSA) o enfermedad progresiva (EP) documentada después de tratamiento hormonal.Chemo-naïve metastatic prostate cancer subjects with documented rising Prostate Specific Antigen (PSA) or documented Progressive Disease (PD) following hormonal therapyMedDRA version: 12.0Level: PTClassification code 10036909Term: Prostate cancer metastatic
EUCTR2008-007969-23-ESCelgene Corporation1,015
进行中(未招募)
1 期
A phase 3 Study to Evaluate the Efficacy and Safety of SHR0302 in Ulcerative Colitis.Moderately to severely active Ulcerative Colitis (UC)MedDRA version: 20.1Level: LLTClassification code 10045365Term: Ulcerative colitisSystem Organ Class: 100000004856
EUCTR2021-001940-86-PLReistone Biopharma Company Limited368
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs;
EUCTR2016-002808-19-PLAziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.p.A.440
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs.ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.1Level: LLTClassification code 10047783Term: Vulvovaginal candidaSystem Organ Class: 100000004862
EUCTR2016-002808-19-ITAZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A.440
进行中(未招募)
1 期
Treatment of infectious diseases and disorders affecting the female sex organs;ncomplicated vulvovaginal candidosis (VVC)MedDRA version: 20.0 Level: LLT Classification code 10047783 Term: Vulvovaginal candida System Organ Class: 100000054373
EUCTR2016-002808-19-BGA.C.R.A.F. S.p.A. (Aziende Chimiche Riunite Angelini Francesco)445